Inactive Instrument

Evotec SE Share Price Other OTC

Equities

EVTCY

US30050E1055

Biotechnology & Medical Research

Financials

Sales 2024 * 883M 944M 74.65B Sales 2025 * 1.04B 1.11B 87.77B Capitalization 1.48B 1.58B 125B
Net income 2024 * -28M -29.93M -2.37B Net income 2025 * 31M 33.14M 2.62B EV / Sales 2024 * 1.93 x
Net Debt 2024 * 227M 243M 19.2B Net Debt 2025 * 186M 199M 15.78B EV / Sales 2025 * 1.6 x
P/E ratio 2024 *
-53.3 x
P/E ratio 2025 *
31.4 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 18/06/19
Director of Finance/CFO 51 06/02/23
Chief Operating Officer 54 30/04/12
Members of the board TitleAgeSince
Chief Executive Officer 61 18/06/19
Director/Board Member 56 18/06/19
Chairman 63 16/06/14
More insiders
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Calendar
More about the company